FIELD: chemistry.SUBSTANCE: invention relates to a compound of formula (Ic) or its tautomeric or stereochemically isomeric forms, N-oxides or pharmaceutically acceptable salts. In formula (Ic), A is CH, U is CR8 and V is N, or A is CH, U is N and V is CR9, or A is N, U is CR8 and V is CR9, or A is CH, U is CR8 and V is CR9； R1 is selected from C1-4alkyl optionally substituted with 1, 2 or 3 halogen atoms； R3a is selected from hydrogen, C1-6 alkyl, -C(=O)NH(2-q)(C1-6 alkyl)q,-CH2-(5-6-membered aromatic or non-aromatic heterocyclyl), -CH2-(9-10-membered bicyclic aromatic or non-aromatic heterocyclyl), and -C(=O)-(4-6-membered aromatic or non-aromatic heterocyclyl)； R6 and R7 are independently selected from hydrogen, C1-6 alkyl, -CH2-phenyl, -CH2-O-CH2-phenyl, or groups R6 and R7, together with the carbon atom with which they are bound, can be combined to form a 3- to 6-membered saturated carbocyclic or heterocyclic group, selected from cyclopropyl, cyclobutyl, cyclopentyl, azetidine, piperidine, which, optionally, may be fused to a phenyl ring. Other radical values are presented in the patent claim. Invention also relates to individual compounds, a pharmaceutical composition, to the use of the compound and to methods for its preparation. (Ic)EFFECT: technical result: obtaining novel compounds of formula (Ic), which can be useful for the prevention or treatment of a disease or condition mediated by one or more IAP family proteins.55 cl, 10 tbl, 266 exИзобретение относится к соединению формулы (Ic) или его таутомерным или стереохимически изомерным формам, N-оксидам или фармацевтически приемлемым солям. В формуле (Ic) A представляет собой СН, U представляет собой CR8 и V представляет собой N, или A представляет собой СН, U представляет собой N и V представляет собой CR9, или A представляет собой N, U представляет собой CR8 и V представляет собой CR9, или A представляет собой СН, U представляет собой CR8 и V представляет собой CR9； R1 выбран из C1-4 алкила, необязател
